127 related articles for article (PubMed ID: 2442437)
21. Accessory factors involved in murine T cell activation. Distinct roles of interleukin 6, interleukin 1 and tumor necrosis factor.
Vink A; Uyttenhove C; Wauters P; Van Snick J
Eur J Immunol; 1990 Jan; 20(1):1-6. PubMed ID: 2407536
[TBL] [Abstract][Full Text] [Related]
22. Symposium on diagnosis and treatment of cancer. Recent progress.
Jpn J Med; 1988 Feb; 27(1):96-112. PubMed ID: 2452911
[No Abstract] [Full Text] [Related]
23. Cytokines as endogenous pyrogens.
Dinarello CA
J Infect Dis; 1999 Mar; 179 Suppl 2():S294-304. PubMed ID: 10081499
[TBL] [Abstract][Full Text] [Related]
24. Immunological monitoring and clinical trials of biological response modifiers.
Kopp WC; Holmlund JT; Urba WJ
Cancer Chemother Biol Response Modif; 1994; 15():226-86. PubMed ID: 7540029
[No Abstract] [Full Text] [Related]
25. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages.
Decker T; Lohmann-Matthes ML; Gifford GE
J Immunol; 1987 Feb; 138(3):957-62. PubMed ID: 3492537
[TBL] [Abstract][Full Text] [Related]
26. Negative regulators of in vivo erythropoiesis: interaction of IL-1 alpha and TNF-alpha and the lack of a strict requirement for T or NK cells for their activity.
Johnson CS; Pourbohloul SC; Furmanski P
Exp Hematol; 1991 Feb; 19(2):101-5. PubMed ID: 1991491
[TBL] [Abstract][Full Text] [Related]
27. Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cells.
Mier JW; Dinarello CA; Atkins MB; Punsal PI; Perlmutter DH
J Immunol; 1987 Aug; 139(4):1268-72. PubMed ID: 2440951
[TBL] [Abstract][Full Text] [Related]
28. Sodium periodate-induced T cell mitogenesis: an analysis of the requirement for Ia and IL 1.
Smith LA; Cohen DA; Lachman LB; Kaplan AM
J Immunol; 1985 Aug; 135(2):1137-44. PubMed ID: 2989361
[TBL] [Abstract][Full Text] [Related]
29. [Biological immunomodulators in the treatment of cancer].
Bello C; Richard C; Hermosa V; Iriondo A; Muruzábal MJ; Pérez Encinas M; Zubizarreta A
Sangre (Barc); 1988 Apr; 33(2):132-43. PubMed ID: 2456623
[No Abstract] [Full Text] [Related]
30. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1.
Ferrara JL; Abhyankar S; Gilliland DG
Transplant Proc; 1993 Feb; 25(1 Pt 2):1216-7. PubMed ID: 8442093
[No Abstract] [Full Text] [Related]
31. Analysis of a cytostatic lymphokine produced by incubation of lymphocytes with tumor cells: relationship to leukoregulin and distinction from recombinant lymphotoxin, recombinant tumor necrosis factor, and natural killer cytotoxic factor.
Sayers TJ; Ransom JH; Denn AC; Herberman RB; Ortaldo JR
J Immunol; 1986 Jul; 137(1):385-90. PubMed ID: 2423611
[TBL] [Abstract][Full Text] [Related]
32. Cytokines and immunological monitoring.
Sosman JA; Sawhaney A
Cancer Chemother Biol Response Modif; 1997; 17():217-86. PubMed ID: 9551216
[No Abstract] [Full Text] [Related]
33. A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM-1) modulates the release of tumor necrosis factor-alpha, interferon-gamma and interleukin 1.
Geissler D; Gaggl S; Möst J; Greil R; Herold M; Dietrich M
Eur J Immunol; 1990 Dec; 20(12):2591-6. PubMed ID: 1980110
[TBL] [Abstract][Full Text] [Related]
34. [Mediators of the immune response and inflammation].
Dayer JM
Ther Umsch; 1986 Feb; 43(2):94-102. PubMed ID: 2421430
[No Abstract] [Full Text] [Related]
35. Recombinant tumor necrosis factor can induce interleukin 2 receptor expression and cytolytic activity in a rat x mouse T cell hybrid.
Plaetinck G; Declercq W; Tavernier J; Nabholz M; Fiers W
Eur J Immunol; 1987 Dec; 17(12):1835-8. PubMed ID: 3121359
[TBL] [Abstract][Full Text] [Related]
36. Cytokines and transcription factors.
Muegge K; Durum SK
Cytokine; 1990 Jan; 2(1):1-8. PubMed ID: 1716484
[TBL] [Abstract][Full Text] [Related]
37. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms by which accessory cells contribute in growth of resting T lymphocytes initiated by OKT3 antibody.
Palacios R
Eur J Immunol; 1985 Jul; 15(7):645-51. PubMed ID: 3924633
[TBL] [Abstract][Full Text] [Related]
39. [Interleukins: factors of intercellular communication].
Ythier A
Ann Biol Clin (Paris); 1985; 43(5):722-4. PubMed ID: 3937465
[TBL] [Abstract][Full Text] [Related]
40. [Recent trends in cancer treatment using cytokines].
Urushizaki I
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):897-905. PubMed ID: 2471455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
